Automatically clustered newsroom coverage around one of the most active themes in the intellectual property ecosystem.
Regentis Biomaterials (NYSE American: RGNT) has obtained a Japanese patent allowance that strengthens its intellectual property protection for the organic solvent-free manufacturing process and ready-to-use liquid formulation behind GelrinC, its cell-free hydrogel for knee cartilage repair. This milestone follows a re…
Boostimmune has been granted a Japanese patent covering antibodies that inhibit translationally controlled tumor protein (TCTP) released from dead tumor cells, suppressing myeloid-derived suppressor cell (MDSC) accumulation in the tumor microenvironment. The patent claims are defined by function and therapeutic applic…
Genprex, Inc. has obtained favorable patent grants from the Japanese Patent Office and European Patent Office covering the use of its REQORSA gene therapy in combination with PD-L1 and PD-1 antibodies to treat cancer. These patents reinforce Genprex’s intellectual property rights in major markets and underpin its Accl…
Subscribe to receive daily and weekly newsroom coverage aligned to this trend cluster and adjacent IP developments.